Volume 90 Issue 12 | p. 21 | Concentrates
Issue Date: March 19, 2012

Pfizer And Biocon Dissolve Pact

Department: Business
Keywords: biosimilars, pharmaceuticals, emerging markets

Less than two years after teaming to develop biosimilar versions of insulin, Pfizer and India’s Biocon are parting ways. In October 2010, Pfizer forked over $200 million up front for the marketing rights to four Biocon insulin products; Biocon was eligible for another $150 million in milestones as the drugs were to be launched around the world. Last week, the companies said that as a result of “individual priorities for their . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society